#United States #New York City #Sera Prognostics #Maternal Health #PreTRM Test

Sera Prognostics to Present at H.C. Wainwright Global Investment Conference

Sera Prognostics Inc., renowned as The Pregnancy Company®, is gearing up to present its groundbreaking innovations at the H.C. Wainwright 27th Annual Global Investment Conference. This prestigious event will take place in New York City from September 8 to 10, 2025, with Sera's presentation scheduled for September 5 at 7:00 AM ET. The company's President and CEO, Zhenya Lindgardt, will be delivering a key update on the company's most recent achievements and developments in improving maternal and neonatal health.

Sera Prognostics is dedicated to enhancing healthcare outcomes for mothers and infants through the provision of innovative pregnancy biomarker information. Especially known for its pioneering PreTRM® Test, the company is transforming the way healthcare professionals approach the risk of preterm birth. This blood-based diagnostic is designed to provide early, accurate, and personalized assessments of a woman’s risk for spontaneous preterm birth, which is defined as any birth occurring before the 37th week of gestation.

The significance of this presentation cannot be overstated; it serves as a platform for Sera to communicate directly with investors, highlighting the company's commitment to addressing a critical healthcare issue. The ability to predict the risk of preterm labor is essential, as preterm birth remains a leading cause of neonatal complications and can have detrimental long-term effects on a child's health, including increased risks of learning disabilities, cerebral palsy, and other serious conditions.

With the 2024 March of Dimes Report indicating that over 10% of infants are born premature in the United States, Sera Prognostics is positioned at the forefront of a growing need for effective solutions. The annual healthcare costs associated with managing complications from prematurity are estimated at around $25 billion, underscoring the urgency for innovative diagnostic tools like the PreTRM® Test.

The PreTRM® Test is the only broadly validated, commercially available blood-based test that measures specific biomarkers in the blood to assess preterm birth risk. This allows healthcare providers to make informed clinical decisions early in the pregnancy, paving the way for timely interventions for those identified at higher risk. By ordering this test, medical professionals can better monitor pregnancies and potentially improve health outcomes for mothers and their newborns.

For stakeholders and investors, the upcoming conference represents not only an opportunity to gain insights into Sera Prognostics' strategy and innovative technologies but also to engage in individual meetings that will further elucidate the company’s roadmap and future growth potential.

The conference presentation will be accessible via a live webcast, with further details available on Sera's official website at www.sera.com, allowing interested parties to follow the updates in real time.

Sera Prognostics continues to champion women's health, focusing efforts on fossilizing solid foundations in pregnancy healthcare. Through its commitment to innovation and collaboration, the company aims not only to enhance health outcomes but also to significantly reduce healthcare costs associated with premature births.

In conclusion, Sera's participation in the H.C. Wainwright Global Investment Conference is a critical step in enhancing visibility for its groundbreaking work in maternal and neonatal health, furthering the conversation around effective healthcare solutions for at-risk pregnancies.